Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.

Glecaprevir with pibrentasvir effective for genotype 1 HCV

06 Dec 2019

The combination of glecaprevir and pibrentasvir (G/P) may be a viable option for patients with genotype 1 hepatitis C virus (HCV) infection who had failed prior treatment with sofosbuvir and a nonstructural protein inhibitor, a new study has shown.

The phase IIIb, open label study included four groups: cirrhotic patients given G/P for 12 (group A; n=78; median age, 62 years; 82 percent male) or 16 (group B; n=49; median age, 62 years; 82 percent male) weeks, and patients with compensated cirrhosis who received G/P with ribavirin for 12 weeks (group C; n=21; median age, 60 years; 76 percent male) or G/P alone for 16 weeks (group D; n=29; median age, 64 years; 79 percent male). The primary outcome was sustained virologic response at 12 weeks (SVR12).

Majority of the participants achieved SVR12 (91.5 percent; n=162). The corresponding rates were 90 percent, 94 percent, 86 percent and 97 percent in groups A, B, C and D, respectively.

Twelve weeks of G/P led to an SVR12 rate of 89 percent, while extending treatment to 16 weeks improved the outcome to 95 percent. Treatment failure was reported in 13 patients with HCV genotype 1a.

G/P was “well tolerated” overall, such that there were no treatment discontinuations due to adverse events (AE) or abnormal laboratory findings. Around two-thirds of the participants experienced side effects, the most common of which were fatigue, nausea and headaches. Twelve serious AEs occurred in eight patients, one of which resulted in death.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.